Develop tadekinig-alpha to treat inflammation
Employees: 11-50
Total raised: $20.89M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | VI Partner... | vipartners... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.01.2016 | Series B | $20.89M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.01.2025 | AB2 Bio signs USD 600 million agreement with Nippon Shinyaku | AB2 Bio has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S. Under the terms of the agreeme... |
| 03.03.2020 | AB2 Bio prepares market entry of its lead product | Lausanne-based AB2 Bio Ltd is specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, including rare diseases with high unmet medical needs. The company is conducting a pivotal Phase 3 ... |
| 03.03.2020 | AB2 Bio prepares market entry of its lead product | |
| 14.01.2016 | AB2 Bio Ltd raises CHF 21 million in Series B financing round |